Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An 8-week open-label study evaluating the efficacy and safety of CBM588 in combination with antidepressants in adult patients diagnosed with major depressive disorder

Trial Profile

An 8-week open-label study evaluating the efficacy and safety of CBM588 in combination with antidepressants in adult patients diagnosed with major depressive disorder

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Oct 2018

At a glance

  • Drugs Clostridium butyricum M588 (Primary) ; Escitalopram; Paroxetine; Sertraline
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Oct 2018 New trial record
    • 01 Sep 2018 Results published in the Clinical Neuropharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top